Healthcare >> Analyst Interviews >> November 15, 2010
A Look At Strong Product Pipelines And M&a In Biotech – Dr. Simos Simeonidis
Dr. Simos Simeonidis, Ph.D., is a Managing Director and Senior Biotechnology Analyst at Rodman & Renshaw, LLC. He joined Rodman from First Albany Capital, where he was a Vice President and Senior Biotechnology Analyst. Prior to that, he was an Associate Biotechnology Analyst at Morgan Stanley. He joined Morgan Stanley from Novartis, where he was an Associate Director in the Business Development/Licensing and Strategic Planning groups. Prior to his career as a Biotechnology Analyst, Dr. Simeonidis was a faculty member at Harvard Medical School/Beth Israel Deaconess Medical Center, and before that, he completed his postdoctoral fellowship in the laboratory of Dr. Tucker Collins at Harvard Medical School/Brigham & Women's Hospital. Dr. Simeonidis received his B.S. in biology from Loyola University in Chicago, his M.A., M.Phil. and Ph.D. in molecular biology from Columbia University's College of Physicians & Surgeons and his MBA in health care management from The Wharton School of the University of Pennsylvania. Profile
TWST: What is your coverage within the biotechnology universe?
Dr. Simeonidis: I currently cover 16 companies in the small- and mid-cap biotechnology space, including Momenta (MNTA), Alnylam (ALNY),